达格列净联合沙库巴曲缬沙坦钠治疗急性心肌梗死患者急诊经皮冠状动脉介入治疗术后心力衰竭的临床疗效

Clinical Efficacy of Daglipzin combined with Sacubactril Valsartan Sodium in the Treatment of Heart Failure after Emergency Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction

目的 探讨达格列净联合沙库巴曲缬沙坦钠治疗急性心肌梗死(AMI)患者急诊经皮冠状动脉介入治疗(PCI)术后心力衰竭的临床疗效。方法 选取2022年1月至2023年1月于北海市第二人民医院心内科接受PCI且术后发生心力衰竭的107例AMI患者作为研究对象,按随机数字表法分为对照组(n=54)和观察组(n=53)。对照组给予沙库巴曲缬沙坦钠口服治疗,观察组给予达格列净联合沙库巴曲缬沙坦钠治疗。比较两组左室舒张末期容积(LVEDV)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室射血分数(LVEF)、N末端脑钠肽原(NT-proBNP)、6 min步行试验(6MWT)及主要不良心血管事件(MACE)、不良反应发生情况。结果 治疗后观察组LVEDV、LVESD、LVEDD、NT-proBNP低于对照组(P<0.05),LVEF、6MWT高于对照组(P<0.05);观察组MACE发生率低于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论 达格列净联合沙库巴曲缬沙坦钠治疗可有效改善AMI急诊PCI术后心力衰竭患者心功能,降低MACE发生风险,其效果优于单纯沙库巴曲缬沙坦钠治疗。

Objective To explore the clinical efficacy of daglizin combined with sacubactril valsartan sodium in the treatment of heart failure after emergency percutaneous coronary intervention(PCI) in patients with acute myocardial infarction(AMI).Methods A total of 107 patients with AMI who underwent PCI and developed heart failure after surgery in the Department of Cardiology,Beihai Second People's Hospital from January 2022 to January 2023 were selected as the study objects,and were divided into control group(n=54) and observation group(n=53) according to random number table method.The control group was given sakubactril and valsartan sodium orally,and the observation group was given dagaglizin combined with Sakubactril and valsartan sodium.Left ventricular end-diastolic volume(LVEDV),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF),N-terminal brain natriuretic peptide(NT-proBNP),6 min walking test(6MWT),major adverse cardiovascular events(MACE) and adverse reactions were compared between the two groups.Results After treatment,LVEDV,LVESD,LVEDD and NT-proBNP in the observation group were lower than those in the control group(P<0.05),and LVEF and 6MWT were higher than those in the control group(P<0.05).The incidence of MACE in observation group was lower than that in control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The treatment of dagliagrazin combined with sackubactril valsartan sodium can effectively improve the cardiac function and reduce the risk of MACE in patients with heart failure after AMI emergency PCI,and the effect is better than that of sackubactril valsartan sodium alone.